Daily BCX7353 Cuts Rate of Hereditary Angioedema Attacks
Oral administration of BCX7353 at dose of 125 mg resulted in lower rate of hereditary angioedema attacks vs placebo.
Angioedema
Cinryze Approved for Pediatric Patients With Hereditary Angioedema
The approval was based on data from a randomized, single-blind, multicenter, dose-ranging, crossover study which evaluated the safety and efficacy of Cinryze in 12 pediatric patients (7 to 11 years old).
Montelukast Improved Symptoms in Angioedema-Predominant Chronic Spontaneous Urticaria
Montelukast improved symptoms in a significant proportion of individuals with angioedema-predominant chronic spontaneous urticaria.
Lanadelumab Reduced Attack Rates in Hereditary Angioedema
Patients with hereditary angioedema experienced a significant reduction in attack rates when treated with lanadelumab.
Hereditary Angioedema Breakthrough Attacks Successfully Treated With Icatibant
Patients with hereditary angioedema treated with icatibant had similar outcomes regardless of whether they were on long-term prophylaxis.
- Loading...
Loading...
Loading... 
Loading...